Tirzepatide vs Semaglutide: What Is the Difference?

Tirzepatide and semaglutide are both GLP-1 receptor agonists used for weight loss and metabolic health, and they are frequently compared. They work through related but distinct mechanisms, produce different average outcomes in clinical trials, and have slightly different side effect profiles. Here is what actually distinguishes them.

How They Work Differently

Semaglutide is a GLP-1 receptor agonist, meaning it targets a single receptor pathway involved in appetite regulation, insulin secretion, and gastric emptying. Tirzepatide is a dual agonist -- it targets both the GLP-1 receptor and the GIP receptor (glucose-dependent insulinotropic polypeptide). The addition of GIP activity appears to enhance weight loss and metabolic effects beyond what GLP-1 activation alone produces, though the exact mechanisms are still being studied.

Weight Loss Outcomes

In clinical trials, tirzepatide has consistently shown greater average weight loss than semaglutide. The SURMOUNT trials for tirzepatide showed average weight loss of 15 to 22 percent of body weight at the highest doses. The STEP trials for semaglutide showed average weight loss of around 15 percent at the highest dose. Individual results vary considerably, and some people respond better to one drug than the other, but tirzepatide holds the edge in average outcomes at the population level.

Dosing and Titration

Both medications are dosed once weekly by subcutaneous injection. Semaglutide typically starts at 0.25 mg weekly and titrates up to a maximum of 2.4 mg for weight management. Tirzepatide starts at 2.5 mg weekly and titrates up to a maximum of 15 mg. The numbering looks very different but the dosing principles are identical -- start low, increase slowly, find your maintenance dose.

Side Effect Profiles

Both medications share similar side effects since they both activate the GLP-1 pathway. Nausea, vomiting, diarrhea, and constipation are the most common complaints with both drugs. Some people report that tirzepatide causes less nausea than semaglutide at equivalent stages of titration, though individual experiences vary widely. Neither drug is dramatically gentler than the other for everyone.

Compounded Versions

Both semaglutide and tirzepatide have been widely available in compounded form through licensed compounding pharmacies, though the regulatory landscape around compounded GLP-1 medications has been evolving. Compounded versions require more careful attention to concentration and volume calculation since they come in vials rather than prefilled pens with preset doses.

Which One Is Right for You

That is a question for your prescriber rather than a website. The right medication depends on your health history, other medications, insurance coverage, and your individual response to treatment. What a dosage calculator can help with -- regardless of which you are using -- is making sure the math between your prescribed dose and your syringe is always correct.